When was Samsung Bioepis founded?

Samsung Bioepis was founded in 2012.

Where is Samsung Bioepis located?

Samsung Bioepis is headquartered in Incheon, South Korea.

How many employees does Samsung Bioepis have?

As of Sep 30, 2026, the latest employee count at Samsung Bioepis is 1587.

How much is Samsung Bioepis worth?

The last known valuation of Samsung Bioepis was $***** as of Jan 27, 2022.

What is the annual revenue of Samsung Bioepis?

Annual revenue of Samsung Bioepis is between $500M and $1B as on Dec 31, 2020

Where does Samsung Bioepis rank among its competitors?

Samsung Bioepis ranks 33rd amongst 1942 active competitors, of which 128 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was AstraZeneca, which secured $6.05M in Jul, 2025.

Who are the top competitors of Samsung Bioepis?

Samsung Bioepis' top competitors include AbbVie, Gilead and Amgen. Among them, AstraZeneca secured the most recent funding round in July, 2025.

Samsung Bioepis - 2026 Company Profile, Funding, Competitors & Financials

Company Details

Developer of biosimilar drugs for the treatment of multiple diseases. It is a Joint venture formed by the collaboration of Samsung Biologics and Biogen to develop biosimilars of advanced biologics to treat conditions such as rheumatoid arthritis, psoriasis, and Crohn’s disease. Ontruzant is Samsung Bioepis’ first cancer biosimilar approved by the FDA. It provides biosimilar of Etanercept, Infliximab, Adalimumab, Trastuzumab, Bevacizumab, etc.

Website: samsungbioepis.com
Social
Phone Number: +82 **********
Part Of

Key Metrics

Founded Year

2012

Location

Incheon, South Korea

Stage

Acquired

Last Known Valuation

$***** as on Jan 27, 2022

Investors

Biogen & 1 more

Ranked

33^rd among 1942 active competitors

Annual Revenue

$500M - $1B as on Dec 31, 2020

Employee Count

1,587 as on Sep 30, 2026

Investment & Acquisitions

C₂N Diagnostics

Similar Companies

Quell & 88 more

Exit Details

Acquired by Samsung BioLogics (Jan 27, 2022)

View Samsung Bioepis' full profile

Samsung Bioepis is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
Samsung Bioepis Co., Ltd CIN: 120111-0601501 , South Korea, Active		$500M - $1B (As on Dec 31, 2020)	-	-

Samsung Bioepis got acquired by Samsung BioLogics on Jan 27, 2022 at an acquisition amount of $*****.

Click here to take a look at Samsung Bioepis's acquisition in detail

Samsung Bioepis is a funded company. Samsung Bioepis has 2 institutional investors.

View details of Samsung Bioepis's funding rounds and investors

Samsung Bioepis' employee count trend

Samsung Bioepis has 1,587 employees as of Sep 26. Here is Samsung Bioepis's employee count trend over the years:

Employee count trend for Samsung Bioepis

Uncover Samsung Bioepis' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Samsung Bioepis include AbbVie, Gilead and Amgen. Here is the list of Top 10 competitors of Samsung Bioepis, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	AbbVie 2012, Chicago (United States), Public	Research-based biopharmaceutical company	$14.7B	Berkshire Hathaway, Alcor Fund & 9 others	83/100
2nd	Gilead 1987, Foster City (United States), Acquired	Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others	-	BB Biotech, Jindal ventures & 17 others	81/100
3rd	Amgen 1980, Thousand Oaks (United States), Public	Developer of pharmaceutical products for treating multiple diseases	-	Digital Pharma Lab, Amgen Business Development ... & 11 others	79/100
4th	AstraZeneca 1999, Cambridge (United Kingdom), Public	Developer of pharmaceutical medicines for oncology and various chronic diseases	-	Digital Pharma Lab, Columbia Capital & 13 others	76/100
5th	Lilly 1876, Indianapolis (United States), Public	Developer of traditional pharmaceutical medicines	-	Alcor Fund, Digital Pharma Lab & 11 others	75/100
6th	Johnson & Johnson 1886, New Brunswick (United States), Public	Manufacturer and supplier of beauty care products, medical devices, and pharmaceutical products	-	Western Technology Investment, Alcor Fund ... & 16 others	74/100
7th	Roivant Sciences 2014, New York City (United States), Public	Developer of therapeutics to treat neurology, oncology, rare, and endocrinology based diseases	$1.3B	SoftBank Vision Fund, NovaQuest Capital Management ... & 8 others	72/100
8th	Novartis 1996, Basel (Switzerland), Acquired	R&D focused on manufacturing of drugs for multiple therapeutic areas	-	Digital Pharma Lab, Atlas Venture & 9 others	71/100
9th	Roche 1896, Basel (Switzerland), Public	Developer of pharmaceuticals and diagnostics kits	-	Gilde Healthcare, SoftBank Group & 11 others	70/100
10th	Genentech 1976, San Francisco (United States), Acquired	R&D company focused on manufacturing drugs for multiple therapeutic areas	$72.5M	Ignite 500, The Column Group & 4 others	68/100
33rd	Samsung Bioepis 2012, Incheon (South Korea), Acquired	Developer of biosimilar drugs for the treatment of multiple diseases	-	Biogen, Samsung BioLogics	59/100